Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
AssigneeTaiho Pharmaceutical Co., Ltd.
InventorsMasanobu Ito, Hiroyuki Okabe
Life of this patent
Estimating the term…
Abstract
This invention provides a method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, the method comprising: (1) detecting the presence or absence of KRAS gene mutation in a biological sample obtained from the patient; and (2) predicting that the patient is likely to sufficiently respond to the chemotherapy, when KRAS gene mutation is detected in Step (1).
Claims9
A method for predicting a therapeutic effect of chemotherapy that uses an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient,
- the method comprising the steps of:
- (1) detecting the presence or absence of KRAS gene mutation in a biological sample obtained from the patient;
- and
- (2) predicting that the patient is likely to sufficiently respond to the chemotherapy, when KRAS gene mutation is detected in Step (1).
An antitumor agent for treating a colorectal cancer patient with KRAS gene mutation, the antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride at a molar ratio of 1:0.5.
A method for treating colorectal cancer, comprising performing chemotherapy that uses an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient with KRAS gene mutation.
Use of an antitumor agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 for treating a colorectal cancer patient with KRAS gene mutation.
Dependencies are inferred from the claim text.